Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The recent STEP trials reported blood pressure reductions for obese patients treated with semaglutide. We analyzed a cohort of patients attending our hypertension clinic and found that 26% were severely or morbidly obese and morbidly obese patients frequently had resistant hypertension (41%). We suggest semaglutide may be an effective anti-hypertensive agent for obese patients with resistant hypertension and this hypothesis should be assessed in randomized clinical trials.